India's nasal vaccine not for those who have taken booster: NTAGI chairman

The Indian nasal vaccine cannot be given to those who have allready taken a precaution or booster dose, the head of the country's vaccine task force said

Bharat Biotech's iNCOVACC, Bharat Bio's nasal Covid vaccine, nasal Covid vaccine, Covid vaccine
Bharat Bio’s nasal Covid vaccine
BS Web Team New Delhi
2 min read Last Updated : Dec 28 2022 | 8:27 AM IST
India's nasal vaccine cannot be given to those who have already taken a precaution or booster dose, the head of the country's vaccine task force said, according to a report by NDTV.

The nasal vaccine iNCOVACC was introduced on the CoWIN platform last week. 

The nasal vaccine is to be used as the "first booster" according to Dr NK Arora, the Chairman of the Covid Working Group of National Technical Advisory Group on Immunisation (NTAGI).

NTAGI works on introducing new vaccines and strengthening the universal immunisation programe in India.

Asserting that CoWIN will not accept a fourth dose, Dr Arora explains the concept of 'antigen sink'. According to him, if an individual is repeatedly immunised with a particular type of antigen, the body stops responding or responds poorly. This he says is the reason why initially mRNA vaccines are given on a gap of six months. 

Taking a fourth dose at this time will be of no value according to Dr Arora, the NDTV reported.

iNCOVACC enters the respiratory system- nose and mouth and here the immune system builds roadblocks to stop the virus from entering the system. And it is expected to help in fighting not only Covid-19 but all other respiratory viruses and infections, according to the report. 

 Who can take iNCOVACC?

As for now anyone above the age of 18 years can get the nasal vaccine, provided they have not allready taken the booster dose. 

The vaccine is administered through the nostril, with just 4 drops in each nostril, Arora said while calling iNCOVACC an extremely safe vaccine.

After the vaccine is administered, one needs to wait for about 15 to 30 minutes to observe and take care if there is any reaction just like with other vaccines, he added.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineBS Web Reportsnasal vaccineVaccine

Next Story